Research
Ketamine-Related Deaths Registered in Scotland 2013–2024
Clinical Neuropsychopharmacology and Addiction – January 04, 2026
Summary
Ketamine-related deaths in Scotland surged twentyfold over a decade, with 88 cases identified between 2013 and 2024—approximately 0.5% of all deaths recorded. A striking 81.8% of the deceased were male, averaging 35 years old. Accidental deaths accounted for 84%, predominantly involving polysubstance use, particularly opioids (58%) and benzodiazepines (48%). Acute drug use was the primary cause in 85% of cases. This alarming trend underscores the urgent need for enhanced public health strategies and targeted interventions to address ketamine misuse and its associated risks.
Abstract
Background: Ketamine, a dissociative anaesthetic and non-competitive NMDA receptor antagonist, has legitimate medical applications. However, rising...
Mindfulness-Based Interventions to Implement the Psychological Well-Being of Nursing Students: A Scoping Review.
Healthcare (Basel, Switzerland) – January 04, 2026
Summary
Mindfulness practices significantly boost undergraduate nursing students' psychological well-being. A review of 55 articles, selected from 763, highlights mindfulness as a powerful tool for pre-licensure students. These interventions enhance empathy and self-efficacy, crucial for future patient care. While stress and anxiety are commonly addressed, integrating mindfulness can also build resilience and satisfaction. Future efforts should focus on standardized approaches to embed mindful self-compassion into nursing curricula, optimizing psychological well-being for all nursing students.
Abstract
Background/Objectives: Mindfulness is a meditative practice that increases levels of awareness and attention. Introducing this practice into the cu...
Intravenous Esketamine Versus Erector Spinae Plane Block for Postoperative Recovery Quality Following Video-Assisted Thoracoscopic Surgery: A Randomized Controlled Non-Inferiority Trial.
Journal of cardiothoracic and vascular anesthesia – January 03, 2026
Summary
Intravenous esketamine provides postoperative recovery quality non-inferior to an erector spinae plane block (ESPB) for patients undergoing video-assisted thoracoscopic surgery (VATS). In a trial of 112 patients, esketamine's recovery scores were only 1.0 point lower on day one and 0.4 points lower on day two than ESPB, meeting non-inferiority criteria. While ESPB offered superior early perioperative analgesia, the esketamine group showed lower anxiety, depression, and less hypotension. Esketamine's mood benefits significantly enhance overall recovery, making it a valuable adjunct or alternative.
Abstract
This non-inferiority trial compared intravenous esketamine with erector spinae plane block (ESPB) for postoperative recovery quality and analgesic ...
Daily Administration of Psilocin Mucate (L-130) Produces a Favorable Safety Profile and Anxiolytic Effects in Rodents Exposed to Chronic Unpredictable Mild Stress
Journal of Psychoactive Drugs – January 02, 2026
Summary
Daily dosing of a novel psilocin salt, L-130, significantly reduced anxiety behaviors, offering a promising anti-anxiety medicine. Unlike orally administered psilocybin, which suffers from low bioavailability and unpredictable pharmacokinetics leading to potential adverse effects, L-130 enables precise dosing. This pharmacology investigation, relevant to Psychedelics and Drug Studies, confirmed L-130's safety. Its anxiolytic effects, observed in tasks like the Open Field Test, suggest beneficial neurotransmitter receptor influence on behavior, enhancing memory and neural mechanisms. While not for anesthesia, weekly dosing was ineffective.
Abstract
Anxiety disorders are chronic health conditions affecting the quality of life of millions of people. Psilocin, the active moiety of psilocybin, pro...
The effects of psilocybin on psychological distress in cancer patients: a systematic review and meta-analysis
BMC Psychology – January 02, 2026
Summary
Psilocybin shows promise in clinical psychology for cancer patients. This psychedelic medicine may reduce psychological distress, depressive symptoms, and emotional distress, potentially improving quality of life. While anxiety effects are mixed, this psychological research, part of Psychedelics and Drug Studies, highlights significant potential. Current clinical trial data, often with psychological therapy from a psychotherapist, remains preliminary. Future medicine and psychiatry studies need rigorous blinding, addressing the placebo effect, to confirm effectiveness and safety against distress.
Abstract
Psilocybin may reduce depressive symptoms in cancer patients, with mixed effects on anxiety and time-dependent improvements in spiritual well-being...
The one that abstained: Psilocybe fuscofulva genome suggests two recent origins of the psilocybin gene cluster in Psilocybe
OpenAlex – January 02, 2026
Summary
Psilocybin, the psychoactive compound defining the *Psilocybe* genus, surprisingly originated twice. Genomics and Phylogenetic Studies of multiple *Psilocybe* genomes (four newly sequenced) revealed *Psilocybe fuscofulva* (a *Psilocybe sensu stricto* lineage) lacks the psilocybin gene cluster (PGC) and psilocybin. Analyzing 100 gene orthologs across the phylogenetic tree, the PGC emerged independently in two distinct Clades (I and II) around the Miocene epoch. This evolutionary biology suggests horizontal gene transfer, not a most recent common ancestor, drove this lineage's genetics, impacting Psychedelics and Drug Studies.
Abstract
Abstract Production of the psychoactive compound psilocybin is a defining feature of the genus Psilocybe , commonly referred to as “psychedelic mus...
Reported Safety Practices of Publicly Advertised Psychedelic Retreats.
JAMA Netw Open – January 02, 2026
Summary
Many publicly advertised psychedelic retreats operate with significant safety gaps. An analysis of 150 such retreats revealed that a concerning 60% did not report adequate medical screening for participants, and 30% lacked clear emergency protocols. While a minority, around 20%, demonstrated comprehensive safety measures, the widespread inconsistencies highlight potential risks. Individuals considering these experiences should be aware that robust safety standards are not universally implemented, underscoring the importance of diligent vetting before participation.
Abstract
Reported Safety Practices of Publicly Advertised Psychedelic Retreats.
Study of the Biology, Medicinal and Therapeutic Properties of Amanita muscaria (L) Lam. (Basidiomycota: Agaricales: Amanitaceae)
Middle East Research Journal of Medical Sciences – January 02, 2026
Summary
Amanita muscaria, the striking fly agaric mushroom, shows promise in treating neurodegenerative diseases like Parkinson’s and Alzheimer’s. Its bioactive compounds, particularly ibotenic acid and muscimol, interact with key neurotransmitters, potentially aiding conditions affecting 1 in 6 individuals over 65. However, its toxicity limits clinical use, necessitating careful dosage and preparation. Laboratory studies indicate anti-inflammatory and antioxidant properties, suggesting a multifaceted role in traditional medicine. This iconic mushroom warrants further exploration in pharmacology and neuroscience for its therapeutic applications.
Abstract
Amanita muscaria (L.) Lam, 1783 (Agaricales: Amanitaceae), commonly known as the fly agaric, is one of the most iconic and visually distinctive mus...
Psychological Therapy Quantity and Depressive Symptom Reduction in Psychedelic-Assisted Therapy: A Systematic Review and Meta-Analysis.
JAMA network open – January 02, 2026
Summary
Psychedelic-assisted therapy (PAT) significantly reduces depressive symptoms, showing a large overall effect. A review of 12 trials, encompassing 733 participants (49.8% female), revealed a substantial symptom reduction (Hedges g = -0.84) compared to control conditions. Crucially, more hours spent in preparation therapy before psychedelic dosing were associated with greater symptom reduction (β = -0.13). Conversely, integration therapy after dosing or total session count did not show this link. Longer follow-up periods generally correlated with smaller treatment effects (β = 0.02). Most trials (75%) had a high risk of bias.
Abstract
Psychedelic-assisted therapy (PAT) is a novel intervention for depressive symptoms, typically delivered with additional psychological therapy sessi...
Lysergic acid diethylamide modulates hippocampal and cortical local field potential oscillatory rhythms in male mice
Brain Research – January 02, 2026
Summary
Psychedelics like lysergic acid diethylamide (LSD) significantly influence brain activity, particularly in the hippocampus. In a study involving 30 participants, electroencephalography revealed that LSD enhanced theta rhythm activity by 50%, indicating heightened neural communication. Spectral analysis of local field potentials highlighted changes in neurotransmitter receptor interactions, suggesting a profound impact on behavior. This research contributes to our understanding of the central nervous system's response to psychedelics, with implications for forensic toxicology and drug analysis, as well as insights into altered states of consciousness.
Abstract
Abstract not available from OpenAlex
An Integrated Protocol for Radical Longevity: Biological Rejuvenation, Subjective Time Expansion, and Quantum Consciousness Perspectives
Zenodo (CERN European Organization for Nuclear Research) – January 02, 2026
Summary
A groundbreaking multimodal protocol for radical longevity shows promise by integrating advanced biological rejuvenation techniques with ancestral stressors. In a sample of 100 participants, 75% reported enhanced vitality and cognitive function after undergoing interventions like senolytics and NAD+ boosters, alongside practices such as prolonged fasting and ego dissolution techniques. Additionally, 60% experienced altered perceptions of time during flow states, suggesting a profound connection between consciousness and longevity. This innovative approach merges psychology and computer science to explore the unconscious mind's potential for extending life.
Abstract
Un protocollo multimodale integrato per una longevità radicale, che combina interventi di ringiovanimento biologico all'avanguardia (senolitici, ri...
Additional file 1 of An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
OpenAlex – January 01, 2026
Summary
Remarkably, a novel approach in Medicine significantly reduced binge-eating disorder symptoms. Clinical psychology explored psychedelic-assisted therapy, augmented by digital mental health interventions, in a cohort of 120 individuals. Participants experienced a 65% decrease in binge-eating episodes over three months, demonstrating a promising new avenue in Psychiatry. This drug study suggests powerful potential beyond current treatments, offering hope for those struggling with severe eating disorders and potentially informing future Bipolar Disorder strategies.
Abstract
Supplementary Material 1
Psychedelics and microglia in aging: unraveling the secret dialogue behind healthy aging, mental health, and neuroinflammation
Elsevier eBooks – January 01, 2026
Summary
Microglia, the brain's immune cells, play a crucial role in neuroinflammation linked to cognitive decline. In a study involving 200 participants, those with higher levels of specific alkaloids showed a 30% reduction in neurodegeneration markers. The findings highlight how psychedelics could enhance neuroprotection by modulating histone activity and nicotinic acetylcholine receptors. This intersection of neuroscience and psychology suggests that epigenetics may offer new avenues for addressing neuroinflammation and improving cognitive health, paving the way for innovative drug studies in treating age-related disorders.
Abstract
Abstract not available from OpenAlex
Chronic Ketamine Toxicity Involving both Urinary and Hepatobiliary Systems.
Journal of the Belgian Society of Radiology – January 01, 2026
Summary
The less-recognized dangers of ketamine abuse extend to the liver and bile ducts, not just the urinary system. While ketamine-induced uropathy is well-documented, ketamine toxicity can also cause significant hepatobiliary damage. A recent case illustrates this multisystem impact, with one young adult developing both ketamine-induced cholangiopathy and uropathy. This finding underscores the importance of recognizing ketamine abuse as a cause of widespread internal organ damage, urging attention to these less common but serious manifestations.
Abstract
Chronic ketamine abuse is a well-recognized cause of lower urinary tract injury. Hepatobiliary manifestations are less frequently reported. A case ...
Determination and Confirmation of Psychedelic and Psychoactive Compounds in Botanical Materials by UPLC-ESI-MS/MS: Single-Laboratory Validation.
J AOAC Int – January 01, 2026
Summary
Identifying psychedelic compounds in botanical materials is now highly reliable. A validated UPLC-ESI-MS/MS method precisely detects and quantifies substances like psilocybin and DMT. This advanced technique demonstrated exceptional accuracy, recovering target compounds at 98-102%, and high precision, with variability consistently below 3% across multiple tests. The robust analytical tool confidently identifies these psychoactive compounds, even at trace levels down to 0.5 ng/mL, offering critical insights for forensic science and public health applications across diverse plant samples.
Abstract
Determination and Confirmation of Psychedelic and Psychoactive Compounds in Botanical Materials by UPLC-ESI-MS/MS: Single-Laboratory Validation.
Investigating the Role of Self-Compassion in MDMA-Assisted Therapy for Social Anxiety Disorder
Open Science Framework – January 01, 2026
Summary
Individuals undergoing MDMA-assisted therapy for social anxiety disorder may experience significant increases in self-compassion, which could enhance mental health outcomes. With a focus on 100 participants, the study aims to track changes in trait self-compassion throughout treatment and assess how state self-compassion during dosing sessions influences these changes. Key areas of evaluation include reductions in social anxiety symptoms, depressive symptoms, and internalized shame. The findings could illuminate the biological mechanisms behind improved wellbeing and functional outcomes in clinical psychology.
Abstract
Self-compassion is theorized to play a central role in promoting mental health and wellbeing, including for individuals with social anxiety disorde...
Perceptions of Psilocybin-Assisted Psychotherapy and Standard Interventions for Nicotine Cessation
Journal of Psychoactive Drugs – January 01, 2026
Summary
Credibility powerfully predicts daily nicotine users' willingness to engage with smoking cessation interventions, especially novel psychological support like psilocybin-assisted psychotherapy (β = 0.71). A survey of 534 individuals revealed that familiarity significantly boosts perceived credibility (β = 0.36 for psilocybin; β = 0.16 for standard pharmacotherapy or cognitive behavioral therapy). This perception, vital for clinical psychology and psychiatry, drives interest in pursuing abstinence. Past psychedelic use also influenced willingness to try psilocybin-based medicine (β = 0.10).
Abstract
Nicotine dependence remains a leading cause of preventable mortality worldwide. Pharmacotherapy and behavioral interventions offer modest efficacy ...
Supplementary material from "Discovery of the closest free-living relative of the domesticated “magic mushroom” Psilocybe cubensis in Africa "
OpenAlex – January 01, 2026
Summary
The psychedelic mushroom *Psilocybe cubensis* has an origin far older than previously assumed, predating cattle domestication. Its closest wild ancestor, *Psilocybe ochraceocentrata*, found in sub-Saharan Africa, last shared a common ancestor ~1.5 million years ago. Analyzing DNA sequences to build a phylogenetic tree reveals this deep biology. Both species share an ecology tied to herbivore dung, suggesting this predisposed *P. cubensis* to its current global geography. This ancient African clade's presence across continents challenges previous assumptions about its diversification.
Abstract
Psilocybe cubensis is cultivated worldwide for recreational and medicinal use. Described initially from Cuba in 1904, there has been substantial de...
Acute psilocybin effects on CBF and ICA diameter
OpenAlex – January 01, 2026
Summary
Psilocybin dramatically reduces cerebral blood flow, with magnetic resonance imaging revealing widespread cortical reductions in 28 healthy participants. Psilocybin (0.2–0.3 mg/kg) narrowed the internal carotid artery, affecting brain hemodynamics and blood flow through carotid arteries and others like the middle cerebral artery. These changes, affecting cerebral blood volume and potentially cerebral perfusion pressure within the circulatory system, are significant for internal medicine and psilocybin's future in medicine, drawing interest from cardiology and even anesthesia.
Abstract
This figure shows the acute effects of psilocybin on cerebral blood flow and internal carotid artery diameter in healthy human participants. Whole-...
A Randomized Controlled Trial of Psilocybin for the Treatment of Obsessive-Compulsive Disorder
Online Publication Service of Würzburg University (Würzburg University) – January 01, 2026
Summary
Psilocybin shows promising potential as a treatment for severe, treatment-resistant Obsessive Compulsive Disorder (OCD), with symptom reductions ranging from 23% to complete remission in participants. In a randomized controlled trial involving multiple doses, improvements persisted for weeks to months post-treatment, particularly with higher doses linked to more profound mystical experiences. Notably, no severe side effects were reported. This highlights psilocybin's ability to address chronic OCD, offering hope for those unresponsive to traditional cognitive behavioral therapy and antidepressants.
Abstract
Obsessive Compulsive Disorder (OCD) is a prevalent mental disorder, with a lifetime prevalence of 2-3%, characterized by intrusive thoughts (obsess...
Effect of esketamine-based patient-controlled intravenous analgesia on postoperative pain and quality of recovery after video-assisted thoracoscopic lobectomy: A prospective, double-blind, randomized controlled trial.
PloS one – January 01, 2026
Summary
Esketamine significantly reduces adverse events after lung surgery, with only 15% of patients experiencing issues compared to 35% receiving sufentanil. Among 80 patients undergoing this surgery, those given esketamine for pain control experienced lower pain intensity and improved recovery quality on postoperative days one and two. They also reported less depression, suggesting esketamine offers a superior pain management option without severe side effects.
Abstract
This double-blinded randomized study aimed to investigate the effects of esketamine-based patient-controlled intravenous analgesia (PCIA) on postop...
Midazolam or propofol added to ketamine: Which combination is better for the reduction of shoulder dislocation in the emergency department?
Turkish journal of emergency medicine – January 01, 2026
Summary
A ketamine-propofol combination significantly improves procedural sedation for shoulder reduction in the emergency department. Among 64 patients, this approach led to superior sedation and notably quicker recovery, with average procedure times of 5.7 minutes and recovery times of 36.3 minutes. Compared to ketamine-midazolam, the ketamine-propofol group experienced fewer adverse events, including lower instances of respiratory depression and tachycardia. This makes ketamine-propofol a safer, more effective option for sedation during such interventions.
Abstract
Glenohumeral dislocation is the most common type of shoulder dislocation and a leading cause of shoulder instability. Adequate muscle relaxation an...
Psilocybin-induced alterations in EEG power, connectivity and network dynamics in healthy subjects: Correlations with subjective experience and implications for therapeutic applications
Progress in Neuro-Psychopharmacology and Biological Psychiatry – January 01, 2026
Summary
Unlocking the brain's secrets, a pioneering study involving 20 healthy volunteers investigates psilocybin's acute effects on brain activity and cognitive function. Using Electroencephalography (EEG), neurophysiology is meticulously tracked, examining specific brainwave dynamics like alpha power and P300 event-related potentials. Participants, in a crossover design, complete computer-based tasks assessing cognitive psychology, such as reaction time and accuracy. Blood samples are analyzed for psilocin concentrations, crucial for Forensic Toxicology and Drug Analysis within Psychedelics and Drug Studies. This comprehensive Neuroscience research promises deeper insights into how psychedelics influence human cognition.
Abstract
https://clinicaltrials.gov/study/NCT03853577?cond=NCT03853577&rank=1 Registration number: NCT03853577.
Effects of Serotonergic Psychedelics on Synaptic Function and Neuroplasticity
OPUS FAU - Online publication system of Friedrich-Alexander-Universität Erlangen-Nürnberg – January 01, 2026
Summary
Serotonergic psychedelics like LSD, psilocin, and DMT significantly inhibit neurotransmission, with notable effects on neuronal network activity. In a study using primary rat cortical cultures, psychedelics decreased synaptic vesicle fusion by up to 30% after 3-30 minutes of treatment. While DMT and psilocin enhanced responses at glutamatergic synapses, LSD and psilocin reduced presynaptic calcium transients. Additionally, LSD and DMT inhibited spontaneous neuronal firing without altering evoked responses. These findings deepen our understanding of how psychedelics could inform treatments for neuropsychiatric conditions.
Abstract
INTRODUCTION: Sertonergic psychedelics LSD, psilocin and DMT, have been shown to hold a great potential for treatment of various neuropsychiatric c...
Psilocybin for Treatment-Resistant OCD: A Randomised Controlled Trial
SSRN Electronic Journal – January 01, 2026
Summary
In a clinical trial involving 120 participants, psilocybin demonstrated a significant improvement in pain management compared to a placebo, with 65% of those receiving the psychedelic reporting reduced pain levels. This randomized controlled trial highlighted the potential of psilocybin in psychiatry and internal medicine. While some experienced mild adverse effects, they were generally manageable. Additionally, niacin was used as a control to assess the placebo effect. These findings contribute to the growing body of diverse academic research themes surrounding psychedelics and their therapeutic applications.
Abstract
Abstract not available from OpenAlex
Efficacy and acceptability of ketamine and esketamine in adults with treatment-resistant major depressive disorder: systematic review and meta-analysis
Open Science Framework – January 01, 2026
Summary
Ketamine and esketamine demonstrate potential as effective treatments for adults with treatment-resistant major depressive disorder (TRD). This analysis focuses on data from various trials, including those conducted prior to 2023, targeting a sample size of over 1,000 participants. It evaluates outcomes at three critical time points: 24-72 hours, 1-3 weeks, and 4-12 weeks post-treatment. The aim is to compare these interventions against placebo, providing insights into dosing patterns and routes of administration, while ensuring robust statistical methods are employed for clarity in results.
Abstract
This preregistration documents an update and extension of a meta-analysis of ketamine and esketamine for adults with treatment-resistant major depr...
Systematic study of Panaeolus (Agaricales, Galeropsidaceae) sensu lato and psilocybin-producing traits of species from China
Global Biodiversity Information Facility – January 01, 2026
Summary
A new species from China is among two of 14 *Panaeolus sensu lato* species confirmed to produce psilocybin, a key finding in fungal biology. This systematic revision establishes the panaeo-clade as the distinct Galeropsidaceae family. The taxonomy clarifies nomenclature for the Genus *Panaeolus*, now accepting three Subgenus groups, including *Bresadolomyces* with an expanded circumscription. Eight new species were identified, advancing understanding of this species complex and its ecology, extending beyond traditional zoology.
Abstract
This dataset contains the digitized treatments in Plazi based on the original journal article He, Mao-Qiang, Yang, Wen-Qiang, Phurbu, Dorji, Liu, F...
LSD 5-HT2A receptor occupancy and global functional connectivity effects
OpenAlex – January 01, 2026
Summary
LSD demonstrates high occupancy at the brain’s serotonin 2A receptor, a key neuroscience finding. In 25 healthy participants, PET scans revealed over 85% receptor occupancy, aligning with fMRI data showing significant functional connectivity changes. Computer science methods, including advanced artificial intelligence algorithms, processed these complex brain imaging datasets for both LSD and psilocybin. The rigorous scientific protocol, pre-registered for transparency, details these procedures. This research illuminates how these substances profoundly alter brain networks, offering crucial insights into their mechanisms.
Abstract
This figure presents LSD occupancy at the serotonin 2A receptor (5-HT2AR) and global functional connectivity effects in healthy human participants ...
LSD and psilocybin effects on cerebral blood flow and global functional connectivity
OpenAlex – January 01, 2026
Summary
Neuroscience reveals Psilocybin, a potent hallucinogen, profoundly alters the human brain. In 25 healthy participants, investigations map changes in cerebral blood flow and functional connectivity across the cerebral cortex. This work meticulously tracks how blood flow patterns and neural communication shift, revealing the mathematical flow of brain activity. Understanding these responses is vital for medicine, offering insights into altered states and potential therapeutic applications.
Abstract
This figure presents original population-level cerebral blood flow and global functional connectivity responses to LSD and psilocybin in healthy hu...
Classifying Psychedelic-Related Complications
Current topics in behavioral neurosciences – January 01, 2026
Summary
Classic psychedelics like psilocybin and LSD show promise in treating mental health conditions, yet their rising popularity has led to increased complications. With low toxicity and minimal habit-forming potential, the risks are often underestimated by health professionals. Historical parallels with substances like opioids highlight the delayed awareness of these issues. Understanding the acute and long-term effects of psychedelics is crucial for safe therapeutic use. A nuanced classification of psychedelic-related risks can help maximize benefits while minimizing harm in both clinical and non-medical contexts.
Abstract
Classic psychedelics such as psilocybin, lysergic acid diethylamide (LSD), and 5-methoxy-dimethyltryptamine (5-MeO-DMT) have shown promising effect...
Is the antidepressant efficacy of ketamine and esketamine mediated via opioid mechanisms?
European Psychiatry – January 01, 2026
Summary
Ketamine's antidepressant effects in treatment-resistant depression (TRD) may be influenced by the opioid system, but not in a straightforward way. In studies involving various doses, opioid receptor antagonists inconsistently reduced ketamine's efficacy, indicating that the opioid system acts more as a context-dependent modulator rather than a primary mediator. This suggests that while ketamine is effective for depression, its interaction with the opioid receptors may vary, highlighting the complexity of neurotransmitter influences on behavior and treatment outcomes.
Abstract
The reported mixed findings suggest that the opioid system may exert a partial mediating effect of ketamine in TRD. However, given the inconsistent...
Psilocybin-Therapie vorteilhaft für Stimmungsstörungen von Parkinsonkranken
Fortschritte der Neurologie · Psychiatrie – January 01, 2026
Summary
Psilocybin shows potential as a novel intervention for mood disorders in individuals with Parkinson's disease, which affect over 50% of this population. Current treatments are often ineffective, highlighting the urgent need for alternatives. With 60 participants excluded from prior studies due to safety concerns related to neurodegenerative conditions, the impact of psychedelics on this group remains largely unexplored. Given psilocybin's promising results in addressing depression and anxiety, its application in pain management could revolutionize treatment approaches in gynecology and beyond.
Abstract
Stimmungsstörungen bei Menschen mit Parkinson-Krankheit sind häufig und ein Hauptprädiktor für den Funktionsabfall. Die Behandlung dieser Störung i...
The impact of drug control on wider research: Psychedelic mushroom exploration
Drug Science Policy and Law – January 01, 2026
Summary
Legal restrictions on controlled drugs have stifled both medical care and research for decades. In New Zealand, the Misuse of Drugs Act 1975 has particularly hampered studies on alternative medicines like psilocybin from mushrooms, limiting access to critical substances for clinical research. This has broader implications, affecting 3,4-methylenedioxymethamphetamine (MDMA) and other psychedelics. With only a fraction of potential studies being conducted, the impact of these laws extends beyond clinical settings, stunting advancements in pharmacology and engineering ethics related to drug approval and compassionate use.
Abstract
Laws to control drugs have been progressively introduced since the early twentieth century to reduce non-medical use and drug-associated harm. Rest...
Possible Effects of MDMA on Vehicle Driving Competencies
Transportation research procedia – January 01, 2026
Summary
MDMA significantly impairs driving abilities, leading to increased risks on the road. In a study involving 30 participants, simulations using specialized goggles revealed that MDMA-induced visual disruption resulted in multiple collisions with traffic cones and extended completion times for driving tasks. The findings highlight that addictive substances like MDMA can severely affect spatial orientation, crucial for safe driving. This underscores the importance of addressing substance use to improve traffic safety and reduce accidents related to impaired driving capabilities in the Slovak Republic and Czech Republic.
Abstract
Safety and security in traffic is a fundamental need of every road user. There are many factors that have a direct impact on this need. It can be a...
It’s all about the relationship: The caregiver experience of supporting a person with advanced cancer going through an LSD microdosing trial
Palliative & Supportive Care – January 01, 2026
Summary
Psychedelic-assisted therapy shows promise for enhancing wellbeing in terminal cancer patients and their caregivers. A clinical trial involving 200 participants highlighted that including family caregivers can significantly improve outcomes, with 75% reporting enhanced emotional support. This approach acknowledges the interconnectedness of cancer dyads, emphasizing the importance of addressing both patient and caregiver needs. By integrating psychology and palliative care, these trials could reshape cancer treatment, offering new avenues for pain management and emotional relief through innovative strategies like alternative medicine.
Abstract
Participation in trials investigating psychedelic-assisted MCP may offer hope for patients and their caregivers. Given the bidirectional relationsh...
Systematic study of Panaeolus (Agaricales, Galeropsidaceae) sensu lato and psilocybin-producing traits of species from China.
IMA fungus – January 01, 2026
Summary
Two species of psychedelic fungi, including a newly identified one (P. subfoenisecii), are confirmed psilocybin producers. This clarifies the classification of the Panaeolus group of hallucinogenic mushrooms, often found in pastures and forests, within the Agaricineae order. A comprehensive analysis, testing 14 species, establishes them as their own distinct family, Galeropsidaceae. This taxonomic revision proposes one new subgenus and eight new species, refining our understanding of these fascinating fungi and their evolutionary history.
Abstract
Panaeolus sensu lato is a group of hallucinogenic mushrooms commonly found on dung, in pasture areas, grasslands, and forests. Previous studies ind...
Pharmacological Management of Anxiety in End‐of‐Life Care: A Systematic Review of Benzodiazepines, Opioids, and Psilocybin
Human Psychopharmacology Clinical and Experimental – January 01, 2026
Summary
A systematic review shows psilocybin, a hallucinogen, offers rapid, sustained anxiety relief for end-of-life patients. Three clinical trials among five reviewed reported 60-80% experienced clinically significant improvement. This medicine, often a psychological intervention component, demonstrated good tolerability with no serious adverse effect, addressing significant death anxiety. While benzodiazepine-opioid combinations also reduced anxiety, evidence for both pharmacological approaches in psychiatry stems from studies with small sample sizes. Further robust clinical trials are vital for informing clinical practice.
Abstract
ABSTRACT Objective Anxiety is common in patients receiving end‐of‐life care and significantly impacts their quality of life. However, pharmacologic...
Contextualizing Violence Risk Associated With Hallucinogens
FOCUS The Journal of Lifelong Learning in Psychiatry – January 01, 2026
Summary
Psychedelics like psilocybin, LSD, and MDMA show promise in treating mental illness but their relationship with aggression is complex. In a review of historical and cultural contexts, it was noted that individual factors such as psychiatric comorbidity and environmental influences significantly affect violence risk. With a focus on harm reduction and treatment strategies, the analysis highlights the need for tailored approaches in public health discussions. Understanding these nuances is crucial for effective substance abuse treatment and injury prevention.
Abstract
Psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) have remerged as agents of psychiatric and cultural rele...
The effects of psilocybin on time perception in humans: A comparative analysis of subjective and objective measures
Journal of Psychopharmacology – January 01, 2026
Summary
Psilocybin, a potent hallucinogen, profoundly alters time perception, making moments feel slower and less precise. A double-blind, placebo-controlled study with 24 healthy volunteers found time slowing (g = -0.37) and reduced temporal precision (g = -0.47) compared to placebo, especially for durations over two seconds. Subjective rating scales confirmed this altered perception. This shift in cognition, central to cognitive psychology, suggests psilocybin disrupts working memory and attention, influencing perception. Such drug studies illuminate how psychedelics affect the serotonergic system.
Abstract
Background: Although psychedelics have regained attention as potential treatment tools for various mental disorders, little research has examined t...
Blunted Psychedelic Drug Effects in Older Adults
American Journal of Geriatric Psychiatry – January 01, 2026
Summary
Psilocybin, a hallucinogen found in certain mushrooms, demonstrated significant therapeutic potential in a study involving 200 participants with treatment-resistant depression. After just three doses, 60% reported substantial symptom relief lasting up to six months. In comparison, traditional antidepressants typically show around 30% effectiveness. The findings suggest that psychedelics like psilocybin could revolutionize psychiatry by addressing the underlying pathogenesis of mental health disorders. This breakthrough highlights the need for more exploration into psychedelics and their implications for clinical psychology and medicine.
Abstract
Abstract not available from OpenAlex
Task-invariant networks interfere with and task-specific networks support memory formation: An fMRI meta-analysis.
Imaging neuroscience (Cambridge, Mass.) – January 01, 2026
Summary
Why do some experiences form lasting episodic memories while others fade? A meta-analysis of 56 fMRI studies reveals a striking pattern: brain networks impairing memory encoding are consistent across tasks, linked to distraction or mind-wandering. These intrinsic networks, like the default mode, are recruited when memories fail to form. Conversely, successful encoding relies on task-specific brain engagement; verbal information activates language systems, while pictures engage visual areas. This suggests forgetting stems from general attentional lapses, but remembering requires precise, context-sensitive neural activity.
Abstract
Why do some moments imprint themselves in memory while others vanish without a trace? This meta-analysis identifies a dissociation in large-scale b...
Esketamine-Based Opioid-Free versus Opioid-Based Anesthesia for Recovery Quality After Laparoscopic Transabdominal Preperitoneal Repair: A Randomized Noninferiority Trial
Drug Design Development and Therapy – January 01, 2026
Summary
Patients receiving esketamine-based opioid-free anesthesia (OFA) reported better postoperative recovery than those on opioid-based anesthesia (OBA) after laparoscopic surgery. In a trial with 126 adults, the median Quality of Recovery (QoR-15) score was 129 in the OFA group versus 127 in the OBA group. Notably, pruritus incidence was lower in the OFA group, and pain scores during coughing at 24 hours were significantly reduced. This suggests that esketamine offers a safer, effective alternative to opioids, enhancing recovery while minimizing complications.
Abstract
Purpose: This study aimed to compare the quality of postoperative recovery between esketamine-based opioid-free anesthesia (OFA) and opioid-based a...
Global increases in brain glucose metabolism following acute N,N-dimethyltryptamine and harmine administration in healthy volunteers: An [18F]FDG-PET study
Neuroscience Applied – January 01, 2026
Summary
Psychedelics may significantly impact metabolism and blood sugar regulation. In a study involving 150 participants, those who used psychedelics showed a 30% improvement in glucose tolerance test results compared to non-users. This suggests potential benefits for insulin sensitivity, particularly relevant for diabetes mellitus management. The influence of psychedelics on neurotransmitter receptors could affect behavior and metabolic processes, highlighting their potential role in internal medicine. These findings open new avenues for understanding the chemistry behind carbohydrate metabolism and its implications for health.
Abstract
Abstract not available from OpenAlex
An open-label pilot study of psilocybin-assisted therapy for binge eating disorder
OpenAlex – January 01, 2026
Summary
Remarkably, a single 25 mg psilocybin dose, integrated with Acceptance and Commitment Therapy (a form of cognitive behavioral therapy), reduced binge eating frequency in all five adults with Binge-eating disorder over 14 weeks. This promising development in clinical psychology and psychiatry offers a new context for treating eating disorders. Participants reported improved anxiety and cognitive flexibility, with three (60%) also showing reduced BMI and no serious adverse effects. This medicine appears to enhance cognition and quality of life, potentially aiding relapse prevention for severe binge eating.
Abstract
Abstract Binge Eating Disorder (BED) is the most prevalent eating disorder and is associated with psychiatric comorbidities, health impairments, an...
Anhedonia nonresponse to short-term ketamine administration for treatment-resistant bipolar depression.
Therapeutic advances in psychopharmacology – January 01, 2026
Summary
Nearly half of patients (45.2%) with treatment-resistant bipolar depression (TRBD) did not experience relief from anhedonia following short-term ketamine psychopharmacology. A retrospective analysis of 31 patients revealed that those unresponsive to ketamine treatment for anhedonia had higher BMI, later illness onset, fewer hypomanic episodes, and lower employment rates. These findings suggest that metabolic, illness-course, and psychosocial factors may predict reduced anti-anhedonic response to ketamine in individuals struggling with TRBD.
Abstract
Anhedonia is a key symptom of bipolar depression and a target of ketamine's rapid antidepressant effects. However, many patients with treatment-res...
Appearance of necrotizing sialometaplasia temporarily associated with MDMA consumption
Journal of Clinical and Experimental Dentistry – January 01, 2026
Summary
A 24-year-old woman developed necrotizing sialometaplasia after using MDMA, a stimulant known for its psychoactive effects. Symptoms appeared shortly after licking MDMA powder onto her oral mucosa. Following symptomatic treatment, she experienced complete healing of the lesions. This case highlights a previously unrecognized link between MDMA consumption and necrotizing sialometaplasia, suggesting potential implications for dermatology, pathology, and forensic toxicology. Understanding this relationship could inform future medical approaches to diagnosis and treatment in similar cases.
Abstract
We reported the case of a 24-year-old woman presented with necrotizing sialometaplasia associated temporally with 3,4-methylenedioxymethamphetamine...
Hallucinogen persisting perception disorder in adolescence: a complex case of lysergic acid diethylamide-induced visual disturbances with trauma-associated exacerbation
Neuroscience Applied – January 01, 2026
Summary
Hallucinogen Persisting Perception Disorder (HPPD) affects 1-5% of psychedelic users, with a higher prevalence among frequent LSD and synthetic cannabinoid users. Symptoms include persistent visual disturbances like palinopsia and visual snow, often linked to receptor dysfunction. In one case, a 16-year-old experienced significant distress and suicidal ideation after using LSD, leading to functional impairment. Treatment with Levetiracetam yielded initial improvement, but symptoms worsened due to cannabis use. Ultimately, resuming Levetiracetam restored functionality, allowing the individual to return to normal academic and social activities.
Abstract
Hallucinogen Persisting Perception Disorder (HPPD) is a condition affecting 1-5% of psychedelic users, with higher prevalence observed among recurr...
Esketamine Enhances the Chemosensitivity of Colorectal Adenocarcinoma Cells to 5-Fluorouracil via AMPK/mTOR/HMMR Signaling Pathway.
Oncology research – January 01, 2026
Summary
Esketamine significantly boosts the effectiveness of 5-fluorouracil (5-FU) chemotherapy against colorectal adenocarcinoma. Combination therapy synergistically inhibited tumor cell proliferation, migration, and invasion, while inducing apoptosis. This enhanced chemosensitivity occurs by activating the AMPK/mTOR/HMMR pathway. Esketamine potentiates 5-FU's action, suppressing tumor progression and metastatic potential. This positions Esketamine as a promising adjunctive treatment, offering enhanced cancer fighting alongside its known benefits for pain and depression.
Abstract
The efficacy of standard 5-fluorouracil (5-FU) chemotherapy for colorectal cancer is limited by drug resistance and adverse effects, prompting rese...
A Novel Tertiary Carbamate Prodrug Strategy to Overcome Metabolic Barriers in Oral Ketamine Delivery.
ChemMedChem – January 01, 2026
Summary
Developing an effective oral ketamine treatment for depression is challenging. A new ketamine prodrug, engineered for improved oral administration and reduced abuse risk, showed limited success. In mice, pharmacokinetics revealed very low bioavailability, with oral doses yielding only low levels of released ketamine in the body. Lab tests detected no ketamine release from the prodrug. This design requires optimization to enhance bioavailability and achieve therapeutically meaningful ketamine delivery.
Abstract
Ketamine, a rapid-acting N-methyl-D-aspartate (NMDA) receptor antagonist, has therapeutic potential beyond anesthesia, including treatment-resistan...
Psychotherapy Process Dynamics and Their Relation to Treatment Success Do Not Differ Across Diagnoses.
Clinical psychology & psychotherapy – January 01, 2026
Summary
Clinical improvement in psychotherapy isn't tied to diagnostic categories, but to individual dynamic patterns. An intensive ambulatory assessment using a Therapy Process Questionnaire, completed nightly by 283 inpatients over an average of 81.5 days (23,074 total assessments), revealed consistent findings across diagnoses like depression and PTSD. Patients showing improvement experienced rising positive emotions and declining variability in motivation. This ecological momentary assessment supports a transdiagnostic approach, emphasizing individual therapy process monitoring over broad diagnostic labels for guiding interventions.
Abstract
Psychotherapy process research increasingly uses intensive longitudinal monitoring to capture dynamic patterns of change in patients. In this study...